U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining 0.16% while the NASDAQ and S&P 500 fell by 0.42% and 0.07%, respectively. Energy shares rose by 1%, but information technology stocks dropped by 0.9%.
Dollar Tree Earnings Report: Dollar Tree, Inc. reported better-than-expected quarterly results with adjusted earnings per share of $1.21, surpassing the analyst estimate of $1.08, and quarterly sales of $4.746 billion, a 9.4% increase year-over-year.
Significant Stock Movements: Capricor Therapeutics saw a dramatic 441% increase in shares after positive trial results, while CIMG Inc. shares fell 35% following a reverse stock split. Other notable declines included Black Diamond Therapeutics, down 28% after disappointing trial data.
Global Market Trends: European shares mostly rose, with the eurozone's STOXX 600 up 0.2%, while Asian markets closed mixed. Economic indicators showed a decline in the S&P Global services PMI and a slight increase in U.S. industrial production, alongside a job loss of 32,000 in November.
Wall Street analysts forecast BDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDTX is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast BDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDTX is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.610
Low
8.00
Averages
9.00
High
10.00
Current: 2.610
Low
8.00
Averages
9.00
High
10.00
Piper Sandler
Kelsey Goodwin
Overweight
downgrade
$9 -> $8
2026-01-16
Reason
Piper Sandler
Kelsey Goodwin
Price Target
$9 -> $8
AI Analysis
2026-01-16
downgrade
Overweight
Reason
Piper Sandler analyst Kelsey Goodwin lowered the firm's price target on Black Diamond Therapeutics to $8 from $9 and keeps an Overweight rating on the shares. Following a flurry of updates from companies across its coverage, the firm updating its 2026 Catalyst Tracker, as well as several models and price targets.
Guggenheim
Brad Canino
Buy -> Neutral
downgrade
2025-12-03
Reason
Guggenheim
Brad Canino
Price Target
2025-12-03
downgrade
Buy -> Neutral
Reason
Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics to Neutral from Buy.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BDTX
Unlock Now
Guggenheim
Brad Canino
Buy -> Neutral
downgrade
2025-12-03
Reason
Guggenheim
Brad Canino
Price Target
2025-12-03
downgrade
Buy -> Neutral
Reason
Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics to Neutral from Buy without a price target. While the headline overall response rate in the silevertinib 1L non-classical EGFRm phase 2 trial is "competitive," there was very high toxicity and there are questions around potential durability, the analyst tells investors in a research note. The firm sees risk to the 2Q26 progression free survival catalyst and Phase 3 start up execution.
Piper Sandler
Overweight
initiated
$9
2025-11-17
Reason
Piper Sandler
Price Target
$9
2025-11-17
initiated
Overweight
Reason
Piper Sandler assumed coverage of Black Diamond Therapeutics with an Overweight rating and $9 price target. Black Diamond is advancing lead asset silevertinib, a "potentially best-in-class" fourth generation EGFR inhibitor for treatment of non-small cell lung cancer and glioblastoma, the analyst tells investors. The less than $100M enterprise value reflected in shares ahead of multiple clinically de-risking and value creating catalysts over the next 12 months "offers an attractive entry point," the analyst contends.
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
